SPRY
ARS Pharmaceuticals·NASDAQ
--
--(--)
--
--(--)
SPRY fundamentals
ARS Pharmaceuticals (SPRY) released its earnings on Mar 9, 2026: revenue was 28.10M (YoY -67.55%), beat estimates; EPS was -0.41 (YoY -185.42%), beat estimates.
Revenue / YoY
28.10M
-67.55%
EPS / YoY
-0.41
-185.42%
Report date
Mar 9, 2026
SPRY Earnings Call Summary for Q4,2025
- $72.2M Revenue Milestone: First full year of commercial sales highlights strong physician engagement despite refill-driven market challenges.
- Sales Force Expansion: 150-rep team to deepen high-volume practice engagement, funded by reallocating $230M SG&A budget.
- Digital Success: Get neffy on Us program drives 10% prescriptions, with DTC awareness at 60% exceeding industry benchmarks.
- Cash Position Strength: $245M cash balance supports 2026 commercial execution and chronic urticaria pipeline advancement.
- Refill Growth Catalyst: Late 2026 refill wave expected to accelerate revenue, aligning with 31-39% refill retention rate in mature market.
Earnings
EPS
Revenue
Revenue & Expenses
SPRY has released its 2025 Q4 earnings report, with revenue of 28.09M, reflecting a YoY change of -67.56%, and net profit of -41.32M, showing a YoY change of -182.76%. The Sankey diagram below clearly presents SPRY's revenue sources and cost distribution.
Key Indicators
ARS Pharmaceuticals (SPRY) key financial stats and ratios, covering profitability, financial health, and leverage.
Income Statement
ARS Pharmaceuticals (SPRY)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Balance Sheet
ARS Pharmaceuticals (SPRY)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Cash Flow
ARS Pharmaceuticals (SPRY)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Revenue Breakdown
Where does ARS Pharmaceuticals (SPRY) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Dividend
Track ARS Pharmaceuticals (SPRY) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield
You can ask Aime
Did ARS Pharmaceuticals beat or miss consensus estimates last quarter?What were the key takeaways from ARS Pharmaceuticals’s earnings call?What were the key takeaways from ARS Pharmaceuticals's earnings call?What is ARS Pharmaceuticals's gross profit margin?What factors drove the changes in ARS Pharmaceuticals's revenue and profit?What is the market's earnings forecast for ARS Pharmaceuticals next quarter?What is the revenue and EPS growth rate for ARS Pharmaceuticals year over year?What guidance did ARS Pharmaceuticals's management provide for the next earnings period?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
